Aaron Wealth Advisors LLC Cuts Position in Novo Nordisk A/S (NYSE:NVO)

Aaron Wealth Advisors LLC trimmed its holdings in Novo Nordisk A/S (NYSE:NVO - Free Report) by 70.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 7,822 shares of the company's stock after selling 18,960 shares during the period. Aaron Wealth Advisors LLC's holdings in Novo Nordisk A/S were worth $809,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Pacific Center for Financial Services boosted its stake in Novo Nordisk A/S by 100.0% during the third quarter. Pacific Center for Financial Services now owns 270 shares of the company's stock valued at $25,000 after buying an additional 135 shares in the last quarter. Copeland Capital Management LLC raised its position in Novo Nordisk A/S by 100.0% in the 3rd quarter. Copeland Capital Management LLC now owns 282 shares of the company's stock valued at $26,000 after purchasing an additional 141 shares during the last quarter. Bell Investment Advisors Inc increased its stake in shares of Novo Nordisk A/S by 79.9% in the 3rd quarter. Bell Investment Advisors Inc now owns 286 shares of the company's stock valued at $26,000 after buying an additional 127 shares during the period. Citizens National Bank Trust Department grew its stake in shares of Novo Nordisk A/S by 100.0% during the third quarter. Citizens National Bank Trust Department now owns 300 shares of the company's stock worth $27,000 after purchasing an additional 150 shares during the period. Finally, Tyler Stone Wealth Management lifted its holdings in Novo Nordisk A/S by 100.0% during the third quarter. Tyler Stone Wealth Management now owns 292 shares of the company's stock worth $27,000 after acquiring an additional 146 shares in the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on NVO shares. Morgan Stanley assumed coverage on Novo Nordisk A/S in a research report on Tuesday, January 23rd. They set an "overweight" rating and a $120.00 price target on the stock. Cantor Fitzgerald restated an "overweight" rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research note on Monday, April 1st. Finally, UBS Group started coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 16th. They issued a "neutral" rating on the stock. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, Novo Nordisk A/S presently has an average rating of "Moderate Buy" and a consensus price target of $126.25.

Novo Nordisk A/S Trading Up 0.0 %

NYSE:NVO traded up $0.06 during mid-day trading on Wednesday, hitting $124.92. 3,024,214 shares of the stock traded hands, compared to its average volume of 5,050,503. The stock has a market capitalization of $560.58 billion, a price-to-earnings ratio of 46.18, a PEG ratio of 2.13 and a beta of 0.41. The company has a quick ratio of 0.64, a current ratio of 0.82 and a debt-to-equity ratio of 0.19. Novo Nordisk A/S has a 52 week low of $75.56 and a 52 week high of $138.28. The firm's 50 day moving average is $125.52 and its two-hundred day moving average is $109.27.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings data on Wednesday, January 31st. The company reported $0.71 EPS for the quarter, topping the consensus estimate of $0.66 by $0.05. Novo Nordisk A/S had a net margin of 36.03% and a return on equity of 90.36%. The firm had revenue of $9.51 billion during the quarter, compared to analyst estimates of $9.14 billion. On average, equities research analysts predict that Novo Nordisk A/S will post 3.32 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently declared a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Stockholders of record on Monday, March 25th were paid a $0.664 dividend. This is an increase from Novo Nordisk A/S's previous Semi-Annual dividend of $0.22. This represents a dividend yield of 0.9%. The ex-dividend date was Friday, March 22nd. Novo Nordisk A/S's dividend payout ratio (DPR) is currently 49.17%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.